文献速递中毒与环境急症重症综合管理与镇静镇痛

单中心学术中心芬太尼阳性患者尿液中的赛拉嗪检测

Xylazine detection in urine of fentanyl-positive patients from a single academic center.
PubMed 文献 · Clin Toxicol (Phila) · 2025-07-21
一句话结论匹兹堡医学中心2010–2024年尿液赛拉嗪阳性病例持续增加,2020–2024年351例中赛拉嗪与芬太尼相对浓度均下降,提示低浓度暴露增多。

该横断面学术实验室研究分析了匹兹堡医学中心2010年至2024年尿液综合药物筛查中赛拉嗪检测情况,重点分析2020年4月1日至2024年3月31日351例赛拉嗪阳性成年病例,其中249例非门诊病例的尿液赛拉嗪与芬太尼相对浓度与临床特征相关。赛拉嗪阳性病例自2016年增加,2019至2021年急剧上升;尿液赛拉嗪相对浓度仅轻微下降,芬太尼相对浓度适度下降。有皮肤伤口和感染的患者尿液赛拉嗪相对浓度显著高于整个队列,但昏迷或心脏骤停后患者无此差异。作者认为赛拉嗪与芬太尼联合暴露的患病率增加,需要更多研究阐明赛拉嗪在阿片中毒中的作用。

要点

  • 2020年4月1日至2024年3月31日共351例尿液赛拉嗪阳性成年病例,赛拉嗪阳性自2016年增加,2019至2021年急剧上升。
  • 非门诊249例中,有皮肤伤口和感染的患者尿液赛拉嗪相对浓度显著高于整个队列。
  • 昏迷或心脏骤停后患者尿液赛拉嗪相对浓度与整个队列无显著差异。
  • 尿液赛拉嗪相对浓度仅轻微下降,尿液芬太尼相对浓度适度下降,作者认为提示低浓度暴露患病率增加。
  • 作者结论认为需要更多研究阐明赛拉嗪在阿片中毒中的作用。

适用人群与场景

  • 2010年至2024年匹兹堡医学中心尿液综合药物筛查中赛拉嗪阳性病例,重点分析2020年4月1日至2024年3月31日351例成年病例。
  • 临床特征分析限于排除门诊后的249例非门诊病例。

研究设计与关键结果

  • 横断面学术实验室研究,分析2010年至2024年尿液综合药物筛查数据,重点为2020年4月1日至2024年3月31日351例赛拉嗪阳性成年病例。
  • 赛拉嗪阳性病例自2016年增加,2019至2021年急剧上升。
  • 尿液赛拉嗪相对浓度仅轻微下降,尿液芬太尼相对浓度适度下降。
  • 249例非门诊病例中,有皮肤伤口和感染的患者尿液赛拉嗪相对浓度显著高于整个队列,昏迷或心脏骤停后患者无显著差异。

证据类型、等级与局限

  • 证据类型:横断面学术实验室研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,赛拉嗪与芬太尼联合暴露的患病率随时间增加,即使尿液相对浓度逐渐下降。
  • 作者认为,需要更多研究阐明赛拉嗪在阿片中毒中的作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Xylazine has increasingly been used as an additive in illicit drugs, leading to severe health consequences. The current study aims to define the total xylazine-positive cases since 2010 and to analyze the trends and clinical implications of xylazine-positive cases at the University of Pittsburgh Medical Center from 2020 to 2024.

METHODS: This cross-sectional academic laboratory-based study analyzed the mass spectrometry dataset, including the normalized peak sizes of xylazine and fentanyl in xylazine-positive urine comprehensive drug screening cases, along with their clinical information. The laboratory information system was also queried to obtain the total number of xylazine detections in urine comprehensive drug screening since 2010.

RESULTS: A total of 351 xylazine-positive adult cases in urine comprehensive drug screening were examined to identify trends in urine xylazine and fentanyl relative concentrations between 1 April 2020 and 31 March 2024. After excluding outpatient cases, the urine xylazine and fentanyl relative concentrations were also correlated with clinical features for the remaining 249 cases. Xylazine-positive cases have increased since 2016, with a sharp rise between 2019 and 2021. Urine xylazine relative concentrations showed a minimal decline, while urine fentanyl relative concentrations modestly decreased. Patients with skin wounds and infections, but not with coma or post-cardiac arrest, had significantly higher urine xylazine relative concentrations than the entire cohort.

DISCUSSION: The number of xylazine-positive and fentanyl-positive cases has increased over time, even as the relative concentrations of urine xylazine and fentanyl have gradually declined. This inverse trend suggests an increasing prevalence of xylazine and fentanyl exposure at progressively lower concentrations. Our data also indicated the association of urine xylazine concentrations with skin wounds and infections, but not with coma or post-cardiac arrest.

CONCLUSIONS: The findings of this study highlight the increasing prevalence of xylazine in illicit drug use, particularly in combination with fentanyl, at our institution over time. More research is needed to elucidate the roles of xylazine on opioid intoxication.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Leal Lopez A, Tamama K. Xylazine detection in urine of fentanyl-positive patients from a single academic center. Clin Toxicol (Phila). 2025. PMID: 40689600. doi:10.1080/15563650.2025.2529016

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。